GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy?
Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
Minnesota Daily4d
Insulin costs capped at $35 per month in Minnesota
Minnesota Attorney General Keith Ellison and pharmaceutical company Novo Nordisk reached a settlement to cap insulin costs at ...